$45.00
Manufacturer: Turkey
Vulvovaginal candidiasis; pityriasis versicolor; dermatomycosis caused by Itraconazole-sensitive pathogens (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), for example, dermatophytosis of the feet, inguinal dermatomycosis, dermatophytosis of the trunk, dermatophytosis of the hands; oropharyngeal candidiasis; onychomycosis caused by dermatophytes and / or yeast;
Description
FUNIT №15 COMPOSITION
active substance: itraconazole
1 capsule contains 100 mg itraconazole
Excipients: hypromellose, polyethylene glycol 6000
neutral micropellets: spherical sugar, corn starch
gelatin capsule: azorubin (E 122), patented blue V (E 131), titanium dioxide (E 171), caramel (E 150), gelatin.
FUNIT №15 DOSAGE FORM
Capsules.
FUNIT №15 MAIN PHYSICAL AND CHEMICAL PROPERTIES:
hard gelatin capsules with a pink lid and a brown body, containing spherical micropellets from white to almost white.
PHARMACOLOGICAL GROUP
Antifungal agents for systemic use. Triazole derivatives ATC code J02A C02.
PHARMACOLOGICAL PROPERTIES
Pharmacological.
Itraconazole is a triazole derivative that has a wide spectrum of action.
Itraconazole inhibits the synthesis of ergosterol in fungal cells. Ergosterol is an important component of the fungal cell membrane, inhibition of its synthesis provides an antifungal effect.
Candida krusei, Candida glabrata and Candida tropicalis are generally the least susceptible Candida species, and some isolates show resistance to itraconazole in vitro.
The main types of fungi that are not suppressed by itraconazole are zygomycetes (Rhizopus spp., Rhizomucor spp., Mucor spp., And Absidia spp.), Fusarium spp., Scedosporium proliferans and Scopulariopsis spp.
Pharmacokinetics.
The peak plasma concentration after oral administration of itraconazole is achieved within 2 to 5:00. Due to non-linear pharmacokinetics, itraconazole accumulates in blood plasma after repeated use. The state of equilibrium concentration, as a rule, is achieved within 15 days, with C max values of 0.5 μg / ml, 1.1 μg / ml and 2.0 μg / ml after application of 100 mg once a day, 200 mg once per day and 200 mg 2 times a day, respectively. The terminal half-life of itraconazole generally ranges from 16 to 28 hours after a single dose and increases to 34-42 hours after multiple doses. After stopping treatment, the concentration of itraconazole decreases to a level that is almost not detected in blood plasma within 7-14 days, depending on the dose and duration of treatment. The average clearance of itraconazole after intravenous administration is 278 ml / min. Due to saturable hepatic metabolism at high doses, the clearance of itraconazole is reduced.
Recent Reviews